|
EQS-News: SYNLAB AG
/ Key word(s): Legal Matter
SYNLAB (FSE: SYAB), the leader in medical diagnostic services and speciality testing in Europe, has announced today that the Portuguese competition authority Autoridade da Concorrência (“AdC”) initiated proceedings against several medical diagnostic providers active in Portugal, including SYNLAB.
The AdC has assessed that two Portuguese subsidiaries of SYNLAB have, together with competitors and a local industry association, potentially violated competition law between 2016 and March 2022. SYNLAB AG as the holding of SYNLAB Group has also been brought into the proceedings. SYNLAB takes these allegations very seriously; compliance with all applicable laws and regulations, both on a national and international level, is a top priority for SYNLAB. SYNLAB is currently reviewing the allegations presented by the AdC carefully and will decide upon next steps after the completion of such review. The estimated outcome of the proceedings, including the risk of a potential penalty being imposed on SYNLAB, cannot be determined before the completion of this review and progress in the proceedings. The allegations raised by the AdC are country-specific and are limited to some operations of two SYNLAB subsidiaries in Portugal. For more information:
About SYNLAB
04.01.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | SYNLAB AG |
| Moosacher Straße 88 | |
| 80809 Munich | |
| Germany | |
| Phone: | +49 1701183753 |
| E-mail: | ir@synlab.com |
| Internet: | www.synlab.com/ |
| ISIN: | DE000A2TSL71 |
| WKN: | A2TSL7 |
| Indices: | SDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1527679 |
| End of News | EQS News Service |
|
|
1527679 04.01.2023 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
